Investment Analysts’ Recent Ratings Updates for Integra LifeSciences (IART)

A number of firms have modified their ratings and price targets on shares of Integra LifeSciences (NASDAQ: IART) recently:

• 7/18/2026 – Integra LifeSciences was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 7/16/2026 – Integra LifeSciences had its price target raised by Truist Financial Corporation from $14.00 to $19.00. They now have a “hold” rating on the stock.
• 7/8/2026 – Integra LifeSciences is now covered by BMO Capital Markets. They set a “market perform” rating and a $19.00 price target on the stock.
• 7/8/2026 – Integra LifeSciences had its “neutral” rating reaffirmed by Citigroup Inc.. They now have a $19.00 price target on the stock, up from $16.00.
• 7/8/2026 – Integra LifeSciences was upgraded by BMO Capital Markets to “hold”.
• 6/18/2026 – Integra LifeSciences was upgraded by Argus from “hold” to “buy”. They now have a $25.00 price target on the stock.
• 6/13/2026 – Integra LifeSciences was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/28/2026 – Integra LifeSciences was upgraded by Citigroup Inc. from “sell” to “neutral”. They now have a $16.00 price target on the stock, up from $11.00.

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.